TY - JOUR
T1 - The CardioMetabolic Health Alliance Working Toward a New Care Model for the Metabolic Syndrome
AU - Sperling, Laurence S.
AU - Mechanick, Jeffrey I.
AU - Neeland, Ian J.
AU - Herrick, Cynthia J.
AU - Després, Jean Pierre
AU - Ndumele, Chiadi E.
AU - Vijayaraghavan, Krishnaswami
AU - Handelsman, Yehuda
AU - Puckrein, Gary A.
AU - Araneta, Maria Rosario G.
AU - Blum, Quie K.
AU - Collins, Karen K.
AU - Cook, Stephen
AU - Dhurandhar, Nikhil V.
AU - Dixon, Dave L.
AU - Egan, Brent M.
AU - Ferdinand, Daphne P.
AU - Herman, Lawrence M.
AU - Hessen, Scott E.
AU - Jacobson, Terry A.
AU - Pate, Russell R.
AU - Ratner, Robert E.
AU - Brinton, Eliot A.
AU - Forker, Alan D.
AU - Ritzenthaler, Laura L.
AU - Grundy, Scott M.
N1 - Funding Information:
The Cardiometabolic Think Tank was sponsored through support from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, and Gilead Sciences. Dr. Sperling has served as a consultant to Esperion. Dr. Mechanick has received honoraria for lectures and program development from Abbott Nutrition International. Dr. Després has served as a consultant to or on the advisory board of Abbott Laboratories, Sanofi, and Torrent Pharmaceuticals Ltd.; has served as a consultant to Merck and Pfizer Canada; and has received speakers fees from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Merck, and Pfizer Canada, Inc. Dr. Vijayaraghavan has served on the speakers bureau for Aegerion, Amarin, Amgen, AstraZeneca, and Otsuka; has served as a consultant to ZS Pharma; has received research support from CompanionDx, GlaxoSmithKline, and Johnson & Johnson; and has served on the advisory board of Sanofi, Lilly, and ZS Pharma. Dr. Handelsman has received honoraria, research support, and/or consultancy fees from Amarin, Amgen, AZ (Amylin), AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Diadexus, DSI, Eisai, Gilead, Grifolis, GlaxoSmithKline, Halozyme, Hanmi, Intarcia, Janssen, Lexicon, LipoScience, Merck, Novo Nordisk, Sanofi, Santarus (Salix), Takeda, and Vivus; has served on the speakers bureau of Amarin, AstraZeneca (Amylin), Bristol-Myers Squibb, Boehringer Ingelheim-Lilly, DSI, GlaxoSmithKline, Janssen, Novo Nordisk, Santarus (Salix), and Vivus; and is President of the American College of Endocrinology, Past President of the American Association of Clinical Endocrinologists, and Associate Editor of the Journal of Diabetes. Dr. Puckrein is founder and Chief Executive Officer of the National Minority Quality Forum. Ms. Collins has served as a consultant to the American Institute for Cancer Research and the National Processed Raspberry Council. Dr. Cook has served on the data monitoring committee of Novo Nordisk. Dr. Dhurandhar has received research funding from Vital Health Interventions, the American Egg Board, and the Mathile Institute for the Advancement of Human Nutrition; has patents filed that relate to obesity of infectious origin and the use of adenoviral proteins to improve glycemic control or metabolic profile; and has served as a consultant/speaker for Vivus and Novo Nordisk. Dr. Dixon has received honoraria from Sanofi; and has served on the speakers bureau for Novartis. Dr. Egan has received consultancy fees and/or grant support from AstraZeneca, BlueCross BlueShield South Carolina, Daiichi-Sankyo, Medtronic, and Novartis; and is an investigator for Medtronic. Mr. Herman has served as a consultant to Boehringer Ingelheim, Merck, Novo Nordisk, and Sanofi; and has served on the speakers bureau for Merck and Novo Nordisk. Dr. Pate has served as a consultant to Curves, Inc.; and has received research funding from The Duke Endowment and the Coca-Cola Company. Dr. Brinton has received grant support from or honoraria as a speaker/consultant for Aegerion, Amarin, Amgen, Arisaph, AstraZeneca, Atherotech, Essentialis, Genzyme, Health Diagnostic Laboratory, Janssen, Kowa, Lilly, Merck, Novartis, PTS Diagnostics, Sanofi, Synageva, and Takeda. Dr. Forker has received research funding from Amylin, AstraZeneca, Daiichi-Sankyo, GlaxoSmithKline, Intarcia, Janssen, Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, ZS Pharma, Sanofi, Takeda, Pfizer, and the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2015 American College of Cardiology Foundation.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - The Cardiometabolic Think Tank was convened on June 20, 2014, in Washington, DC, as a "call to action" activity focused on defining new patient care models and approaches to address contemporary issues of cardiometabolic risk and disease. Individual experts representing >20 professional organizations participated in this roundtable discussion. The Think Tank consensus was that the metabolic syndrome (MetS) is a complex pathophysiological state comprised of a cluster of clinically measured and typically unmeasured risk factors, is progressive in its course, and is associated with serious and extensive comorbidity, but tends to be clinically under-recognized. The ideal patient care model for MetS must accurately identify those at risk before MetS develops and must recognize subtypes and stages of MetS to more effectively direct prevention and therapies. This new MetS care model introduces both affirmed and emerging concepts that will require consensus development, validation, and optimization in the future.
AB - The Cardiometabolic Think Tank was convened on June 20, 2014, in Washington, DC, as a "call to action" activity focused on defining new patient care models and approaches to address contemporary issues of cardiometabolic risk and disease. Individual experts representing >20 professional organizations participated in this roundtable discussion. The Think Tank consensus was that the metabolic syndrome (MetS) is a complex pathophysiological state comprised of a cluster of clinically measured and typically unmeasured risk factors, is progressive in its course, and is associated with serious and extensive comorbidity, but tends to be clinically under-recognized. The ideal patient care model for MetS must accurately identify those at risk before MetS develops and must recognize subtypes and stages of MetS to more effectively direct prevention and therapies. This new MetS care model introduces both affirmed and emerging concepts that will require consensus development, validation, and optimization in the future.
KW - cardiometabolic
KW - cardiovascular disease
KW - insulin resistance
KW - obesity
UR - http://www.scopus.com/inward/record.url?scp=84940062534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940062534&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2015.06.1328
DO - 10.1016/j.jacc.2015.06.1328
M3 - Review article
C2 - 26314534
AN - SCOPUS:84940062534
SN - 0735-1097
VL - 66
SP - 1050
EP - 1067
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 9
M1 - 21548
ER -